insights_auto
Why is BMRN down 2,16%?
Dive Deeperchevron_right
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
57,18 US$
arrow_downward
-2,16%(-1,26) 1D
2 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
58,52 US$
High
58,73 US$
Low
57,15 US$
Mkt. cap
11,07 მლრდ.
Avg. vol.
1,90 მლნ.
Volume
193,00
P/E ratio
154,15
52-wk high
70,98 US$
52-wk low
49,26 US$
EPS
0,37 US$
Beta
0,22
Shares outstanding
193,57 მლნ.
No. of employees
3 ათ.
Open
58,52 US$
High
58,73 US$
Low
57,15 US$
Mkt. cap
11,07 მლრდ.
Avg. vol.
1,90 მლნ.
Volume
193,00
P/E ratio
154,15
52-wk high
70,98 US$
52-wk low
49,26 US$
EPS
0,37 US$
Beta
0,22
Shares outstanding
193,57 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOალექსანდერ ჰარდი
Employees3,22 ათ.
Foundedმარ 1997
HeadquartersSan Rafael, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitebiomarin.com